SCHEMBL17801630

SCHEMBL17801630

CCCCOC(=O)N1CCC(F)C(O)C1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.49
LMNA P02545 1/20 0.49
POLB P06746 1/20 0.49
GBA2 Q9HCG7 1/20 0.42
GAA P10253 1/20 0.38
HPGD P15428 1/20 0.36
ALDH1A1 P00352 3/20 0.36
CHRM2 P08172 1/20 0.36
CHRM1 P11229 1/20 0.36
HRH2 P25021 1/20 0.36
HRH1 P35367 1/20 0.36
PDE4B Q07343 1/20 0.35
ATM Q13315 2/20 0.35
GNAI3 P08754 1/20 0.35
GNAO1 P09471 1/20 0.35
GNAI1 P63096 1/20 0.35
THRB P10828 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
MMP3 P08254 2/20 0.35
MMP9 P14780 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31372353 1.00 SMN1; SMN2 (0.49) SMN1; SMN2LMNAPOLBGBA2GAA
SCHEMBL30066644 0.89 LMNA (0.49) SMN1; SMN2LMNAPOLBGBA2GAA
SCHEMBL6120432 0.89 LMNA (0.49) SMN1; SMN2LMNAPOLBGBA2GAA
SCHEMBL29838479 0.86 SMN1; SMN2 (0.49) SMN1; SMN2LMNAPOLBGBA2GAA
SCHEMBL22440438 0.85 SMN1; SMN2 (0.54) SMN1; SMN2LMNAPOLBGBA2GAA
SCHEMBL3652388 0.82 LMNA (0.54) SMN1; SMN2LMNAPOLBGBA2GAA
SCHEMBL3708900 0.82 LMNA (0.54) SMN1; SMN2LMNAPOLBGBA2GAA
SCHEMBL3652385 0.82 LMNA (0.54) SMN1; SMN2LMNAPOLBGBA2GAA
SCHEMBL25350252 0.82 LMNA (0.48) SMN1; SMN2LMNAPOLBGBA2GAA
SCHEMBL3635383 0.82 SMN1; SMN2 (0.48) SMN1; SMN2LMNAPOLBGBA2GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3227279-A1 1 -OXO-1,2-DIHYDROISOQUINOLIN-7-YL-(5-SUBSTITUTED-THIOPHEN-2-YL)-SULFONAMIDE COMPOUNDS, FORMULATIONS CONTAINING THOSE COMPOUNDS, AND THEIR USE AS AICARFT INHIBITORS IN THE TREATMENT OF CANCERS Eli Lilly and Company (US) 2017-10-11 EP disclosed
WO-2016089670-A1 1 -OXO-1,2-DIHYDROISOQUINOLIN-7-YL-(5-SUBSTITUTED-THIOPHEN-2-YL)-SULFONAMIDE COMPOUNDS, FORMULATIONS CONTAINING THOSE COMPOUNDS, AND THEIR USE AS AICARFT INHIBITORS IN THE TREATMENT OF CANCERS ELI LILLY AND COMPANY (US) 2016-06-09 WO disclosed